Terms: = Lymphoma AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
22173 results:
1. treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of a machine-learning model based on laboratory parameters for the prediction of acute leukaemia subtypes: a multicentre model development and validation study in France.
Alcazer V; Le Meur G; Roccon M; Barriere S; Le Calvez B; Badaoui B; Spaeth A; Kosmider O; Freynet N; Eveillard M; Croizier C; Chevalier S; Sujobert P
Lancet Digit Health; 2024 May; 6(5):e323-e333. PubMed ID: 38670741
[TBL] [Abstract] [Full Text] [Related]
3. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
[TBL] [Abstract] [Full Text] [Related]
4. Real-life study on the use of response adapted therapy in patients with Hodgkin lymphoma: Results from a multicenter experience.
Zilioli VR; Cencini E; Lorenzo S; Pezzullo L; Merli M; Rivellini F; Muzi C; Emiliano B; Marcheselli L; Luminari S
Hematol Oncol; 2024 May; 42(3):e3273. PubMed ID: 38661120
[TBL] [Abstract] [Full Text] [Related]
5. [Correlation Analysis of Peripheral Blood B Cell Count with Clinical Features and Prognosis in Patients Newly Diagnosed with Diffuse Large B-Cell lymphoma].
Lu T; Mi H; Zhao DD; Yang SG; Bu YW; Zhang F; Chen WM; Sun DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):458-465. PubMed ID: 38660852
[TBL] [Abstract] [Full Text] [Related]
6. [A Real-World Single-Center Study of Adult Hodgkin's lymphoma].
Wang LL; Tian L; Dong F; Yang P; Wan W; Li QH; Ma L; Gao JJ; Wang JJ; Zhao W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):428-433. PubMed ID: 38660847
[TBL] [Abstract] [Full Text] [Related]
7. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
Wang H; Feng J; Liu Y; Qian Z; Gao D; Ran X; Zhou H; Liu L; Wang B; Fang M; Zhou H; Huang Z; Tao S; Chen Z; Su L; Su H; Yang Y; Xie X; Wu H; Sun P; Hu G; Liang A; Li Z
Signal Transduct Target Ther; 2024 Apr; 9(1):99. PubMed ID: 38627366
[TBL] [Abstract] [Full Text] [Related]
8. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.
Qadir MI; Ahmed B; Hussain N
Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
[TBL] [Abstract] [Full Text] [Related]
10. Infant Acute Lymphoblastic Leukemia-New Therapeutic Opportunities.
Kulczycka M; Derlatka K; Tasior J; Sygacz M; Lejman M; Zawitkowska J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612531
[TBL] [Abstract] [Full Text] [Related]
11. Real-World Challenges of Managing Diffuse Large B-Cell lymphoma in a Developing Country.
Iftikhar R; Ahmad U; Haider G; Mahmood H; Khan M; Masood M; Anwar N; Javed Q; Sajid N; Tariq R; Mehmod S; Haider J; Abro NA; Shahbaz S; Khokhar A; Khan ZA; Pervez H; Moosajee M; Aziz Z
JCO Glob Oncol; 2024 Apr; 10():e2300386. PubMed ID: 38603657
[TBL] [Abstract] [Full Text] [Related]
12. Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy.
Sineshaw HM; Zettler CM; Prescott J; Garg M; Chakraborty S; Sarpong EM; Bai C; Belli AJ; Fernandes LL; Wang CK
Cancer Med; 2024 Apr; 13(7):e7173. PubMed ID: 38597118
[TBL] [Abstract] [Full Text] [Related]
13. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T; Matsuno Y; Wakabayashi M; Maruyama D; Yamamoto K; Kubota N; Shimada K; Asagoe K; Yamaguchi M; Ando K; Ogura M; Kuroda J; Suehiro Y; Tsukasaki K; Tobinai K; Nagai H
Hematol Oncol; 2024 May; 42(3):e3272. PubMed ID: 38595316
[TBL] [Abstract] [Full Text] [Related]
14. Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma.
Chen J; Zhou J; Cheng F; Chen D; Guan F; Zhang E; He J; Cai Z; Zhao Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):181. PubMed ID: 38587664
[TBL] [Abstract] [Full Text] [Related]
15. Missed opportunities for HIV testing and sexual health-related challenges in an individual with intellectual disability: a case report.
Würfel LM; Potthoff A; Nambiar S; Skaletz-Rorowski A
AIDS Res Ther; 2024 Apr; 21(1):20. PubMed ID: 38581028
[TBL] [Abstract] [Full Text] [Related]
16. Blood MALT1 expression could help predict treatment outcomes in psoriasis patients, especially in those receiving biologics.
Liu Q; Zhang Y; Xu B; Jin X; Yang T; Fan L
Immun Inflamm Dis; 2024 Apr; 12(4):e1235. PubMed ID: 38578002
[TBL] [Abstract] [Full Text] [Related]
17. treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract] [Full Text] [Related]
18. Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.
Liu Y; Zhang S; Tan Y
Hematology; 2024 Dec; 29(1):2337307. PubMed ID: 38573223
[No Abstract] [Full Text] [Related]
19. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract] [Full Text] [Related]
20. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract] [Full Text] [Related]
[Next]
